BIOGEN INC. - COMMON STOCK

Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA® (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis

07 2月 2022 15:05:00 条件 Nasdaq GlobeNewswire

Biogen Exercises Option to Participate in the Development and Commercialization of a Late-Stage Bispecific Antibody

01 2月 2022 06:30:00 条件 Nasdaq GlobeNewswire

Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors

31 1月 2022 06:30:00 条件 Nasdaq GlobeNewswire

Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion

27 1月 2022 17:50:14 条件 Nasdaq GlobeNewswire

Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM®

27 1月 2022 06:30:00 条件 Nasdaq GlobeNewswire

Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA

04 1月 2022 06:34:32 条件 Nasdaq GlobeNewswire

Japan’s First Committee on New Drugs of The Pharmaceutical Affairs and Food Sanitation Council Seeks Additional Data; Aducanumab Remains under Review

22 12月 2021 06:30:00 条件 Nasdaq GlobeNewswire

Biogen Announces Reduced Price for ADUHELM® to Improve Access for Patients with Early Alzheimer’s Disease

20 12月 2021 06:00:00 条件 Nasdaq GlobeNewswire

Update on Regulatory Submission for Aducanumab in the European Union

17 12月 2021 05:43:58 条件 Nasdaq GlobeNewswire

Update on the Phase 4 Confirmatory Study of ADUHELM®

16 12月 2021 06:00:00 条件 Nasdaq GlobeNewswire